Probity Advisors’s Quest Diagnostics DGX Stock Holding History

Probity Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,595	Closed	-$205K	–	201
2021 Q1	$205K	Buy	+1,595	New	+$197K	0.05%	193
2020 Q3	$269K	Sell	2,346 -1,012	-30%	-$120K	0.08%	154
2020 Q2	$383K	Sell	3,358 -28	-0.8%	-$2.97K	0.12%	127
2020 Q1	$272K	Sell	3,386 -170	-5%	-$17.6K	0.1%	139
2019 Q4	$380K	Buy	3,556 +1,452	+69%	+$151K	0.11%	136
2019 Q3	$225K	Buy	2,104 +77	+4%	+$7.91K	0.07%	165
2019 Q2	$206K	Buy	+2,027	New	+$195K	0.07%	166

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Probity Advisors's DGX Position: Q2 2021 in Review

Probity Advisors sold out of Quest Diagnostics (DGX) in Q2 2021, closing a stake of 1,595 shares — an estimated $205K sold.

Probity Advisors first reported a position in DGX in Q2 2019 and held it in 7 quarters. The position peaked at $383K in Q2 2020. 814 funds tracked by Wall St. Rank hold DGX as of Q2 2021.

Probity Advisors reported no remaining Quest Diagnostics position as of Q2 2021 after selling out during the quarter.
Probity Advisors sold 1,595 Quest Diagnostics shares in Q2 2021, an estimated $205K.
Probity Advisors first reported a position in Quest Diagnostics in Q2 2019 and held it in 7 quarters.
Probity Advisors's Quest Diagnostics position peaked at $383K in Q2 2020.
814 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2021.

Based on Probity Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.